Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriasis.

Abstract: In one embodiment, a collaboration session is maintained among a plurality of participant devices, at least one participant device operating as a presenter device that shares content during the collaboration session. Content shared during the collaboration session is recorded. A request is detected during the collaboration session from a particular participant device of the plurality of participant devices to view at least a portion of the recorded content. In response to the request during the collaboration from the particular participant device to view the at least a portion of the recorded content, the at least a portion of the recorded content is played back while the collaboration session is still ongoing, wherein the particular participant device remains an active participant in the ongoing collaboration session during playback of the at least a portion of the recorded content. Eventually, playback of the at least a portion of the recorded content is ceased.

Abstract: In one embodiment, one or more applications may be executed on a computer, where each application has an associated feature set. A user status of a particular application may be determined, and in response to that user status for the particular application, the feature set of at least one other application may be dynamically adjusted.

Abstract: In one embodiment, a first application detects a user's activity. Based on the user's activity detected by the first application, a type of user status is determined from among a plurality of different types of possible user status. One or more features are determined of a feature set of a second application that correspond to the type of user status detected by the first application. The corresponding one or more features of the feature set of the second application are limited to prevent the one or more features from interrupting the user's activity. One or more other features of the feature set of the second application that do not correspond to the type of user status detected by the first application are permitted.

Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriasis.

Abstract: In one embodiment, the methods and systems detect a meeting; detect a missing participant scheduled to attend the meeting; identify a device actively utilized by the missing participant; and transmit a reminder message to the device.

Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Abstract: A computer system and related display techniques are presented here. The system generates and provides a graphical user interface (GUI) control element to enable user adjustment of sales forecast data, and provides a hover box associated with the GUI control element, the hover box graphically indicating adjustment status information for the sales forecast data. The system also provides a forecast table panel in the GUI. In response to receiving a request corresponding to selected forecast data included in the forecast table panel, the system generates an opportunities list panel in the GUI. The opportunities list panel includes a listing of individual opportunities and related status corresponding to the selected forecast data.

Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

Abstract: This application discloses a composite material comprising one or more silk elements in an acrylic or cross-linked protein matrix. The silk elements are made from the group of silk elements consisting of domestic silkworm silk, wild silkworm silk, spider dragline silk, and filaments spun from recombinant silk protein or protein analogues. The composite material is particularly useful for use in-surgical-implants.

Abstract: Systems and methods for converting interactive multimedia content authored for distribution via a physical medium for electronic distribution are disclosed. One embodiment of the invention includes building an object model of interactive multimedia content authored for distribution via a physical medium using a content authoring system, automatically authoring a user interface based upon the object model using the content authoring system, and packing the transcoded multimedia content into at least one container file.

Abstract: Systems and methods for electronic sell-through (EST) of multimedia content authored for distribution via physical media in accordance with embodiments of the invention are disclosed. One embodiment of the invention includes building an object model of interactive multimedia content authored for distribution via a physical medium using a content authoring system, automatically authoring a user interface based upon the object model using the content authoring system, packing the multimedia content into at least one container file, and electronically distributing at least a portion of the authored user interface and the at least one container file via a network connection.

Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: A method includes receiving, at a control node of a cloud computing network, a first enterprise policy specific to the first enterprise and a second enterprise policy specific to the second enterprise, and managing communications between at least one user device of the first enterprise and the at least one enterprise application hosted on behalf of the first enterprise based on the first enterprise policy. The method also includes managing communications between at least one user device of the second enterprise and the at least one enterprise application hosted on behalf of the second enterprise based on the second enterprise policy.

Abstract: A source sampling rate is associated with first or second groups of sampling rates. A playback rate is determined by: (a) selecting the source sampling rate if the source sampling rate is supported by a playback environment; (b) otherwise if there is a highest first rate from the first or second groups of playback sampling rates which is supported by the playback environment and is lower than the source sampling rate, selecting the first rate; (c) otherwise if there is a slowest second rate from the group that the source sampling rate is associated with that is supported by the playback environment and is higher than the source sampling rate, selecting the second rate; (d) otherwise selecting the slowest sampling rate supported by the playback environment from the group that the source sampling rate is not associated with as the playback rate.